A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

Ipilimumab (IPI) can enhance immunity to the cancer-testis antigen NY-ESO-1. A clinical trial was designed to assess safety, immunogenicity, and clinical responses with IPI + NY-ESO-1 vaccines and effects on the tumor microenvironment (TME). Patients with measurable NY-ESO-1(+) tumors were enrolled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Slingluff, Craig L., Zarour, Hassane M., Tawbi, Hussein Abdul-Hassan, Kirkwood, John M., Postow, Michael A., Friedlander, Philip, Devoe, Craig E., Gaughan, Elizabeth M., Mauldin, Ileana S., Olson, Walter C., Smith, Kelly T., Macri, Mary J., Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Wolchok, Jedd D.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007150/
https://ncbi.nlm.nih.gov/pubmed/33796406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1898105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados